Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 10Meningioma 4Gastro-enteropancreatic neuroendocrine tumor 3Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Germ Cell and Embryonal 2Medulloblastoma 2Glioma 2Ependymoma 2Adenoma, Islet Cell 2Stomach Neoplasms 1Sarcoma, Synovial 1Recurrence 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Intestinal Neoplasms 1Intestinal Diseases 1Hypertension 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1

Interventions

Cisplatin 4Etoposide 3atezolizumab 2Drug Therapy 2Carboplatin 2tivozanib 1repotrectinib 1lutetium Lu 177 dotatate 1durvalumab 1dostarlimab 1belinostat 1Somatostatin 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Magnetic Resonance Imaging 1Ipilimumab 1FOLFOXIRI protocol 1EC regimen 1DLL3 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Neuroendocrine × lutetium Lu 177 dotatate × Clear all
NCT01876771 2025-08-08

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

AHS Cancer Control Alberta

Phase 2 Recruiting
500 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡